P Markus Deckert
Overview
Explore the profile of P Markus Deckert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Streptococcus pneumoniae and influenza vaccination rates in oncological patients - data from Germany
Niederstein E, Underwood J, de Wit M, Reinwald M, Schwarzlose-Schwarck S, Dammermann W, et al.
Support Care Cancer
. 2024 Nov;
32(12):813.
PMID: 39570461
Objectives: Due to disease- or therapy-associated immunosuppression, oncological patients suffer from significantly higher morbidity and mortality due to infections transmitted by respiratory pathogens such as Streptococcus pneumoniae and influenza virus....
2.
Godde K, Fugemann H, Goerling U, Grittner U, Kohl R, Meisel A, et al.
PLoS One
. 2023 Jun;
18(6):e0287638.
PMID: 37384672
Background: Patient navigation programmes were introduced in the United States and recently gained interest in Germany, where the health care system is fragmented. Navigation programmes aim to decrease barriers to...
3.
Chilimoniuk J, Gosiewska A, Slowik J, Weiss R, Deckert P, Rodiger S, et al.
Ann Transl Med
. 2021 May;
9(7):528.
PMID: 33987226
Background: DNA double-strand breaks can be counted as discrete foci by imaging techniques. In personalized medicine and pharmacology, the analysis of counting data is relevant for numerous applications, e.g., for...
4.
Panjideh H, Da Silva Coelho V, Dernedde J, Bachran C, Forster G, Franke J, et al.
Int J Oncol
. 2008 Mar;
32(4):925-30.
PMID: 18360720
In antibody-directed enzyme-prodrug therapy (ADEPT), an antibody-bound enzyme localizes to tumor tissue, where it selectively converts a subsequently administered non-toxic prodrug into a cytotoxic drug. A33scFv::CDy is a bifunctional fusion...
5.
Frey D, Coelho V, Petrausch U, Schaefer M, Keilholz U, Thiel E, et al.
Cancer Biother Radiopharm
. 2008 Feb;
23(1):65-73.
PMID: 18298330
The cell-surface marker, gpA33, a new member of the immunoglobulin superfamily, is expressed by gastrointestinal cells and by 95% of colon cancers. It has become a promising target of immunologic...
6.
Panjideh H, Coelho V, Dernedde J, Fuchs H, Keilholz U, Thiel E, et al.
Bioprocess Biosyst Eng
. 2008 Feb;
31(6):559-68.
PMID: 18253756
Recombinant antibody fusion constructs with heterologous functional domains are a promising approach to new therapeutic targeting strategies. However, expression of such constructs is mostly limited to cost and labor-intensive mammalian...
7.
Petrausch U, Dernedde J, Coelho V, Panjideh H, Frey D, Fuchs H, et al.
Protein Eng Des Sel
. 2007 Nov;
20(12):583-90.
PMID: 18033820
Chemical conjugates of monoclonal antibodies with fluorophores or enzymes have long been used for diagnostic purposes and experimental therapeutic approaches. Recombinant technology allows for the design and expression of tailored...
8.
Coelho V, Dernedde J, Petrausch U, Panjideh H, Fuchs H, Menzel C, et al.
Int J Oncol
. 2007 Sep;
31(4):951-7.
PMID: 17786329
Antibody-directed enzyme-prodrug therapy (ADEPT) aims at improving the specificity of conventional chemotherapy by employing artificial antibody-enzyme constructs to convert a non-toxic prodrug into a cytotoxic agent specifically localized to the...
9.
Deckert P, Bornmann W, Ritter G, Williams Jr C, Franke J, Keilholz U, et al.
Int J Oncol
. 2004 Apr;
24(5):1289-95.
PMID: 15067353
In antibody-directed enzyme-prodrug therapy (ADEPT), antibody-enzyme conjugates specifically activate non-toxic prodrugs in tumour tissue. The A33 cognate antigen is a promising target for immunotherapy of gastrointestinal cancers. We have explored...